{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"77.8","upperLimit":"93.3","value":"86.9"}]}],"title":"Stable MR4.5 for 48 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65.7","upperLimit":"84.8","value":"76.2"}]}],"title":"Stable MR4.5 for 96 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"60.5","upperLimit":"80.8","value":"71.4"}]}],"title":"Stable MR4.5 for 144 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.9","upperLimit":"73.4","value":"63.1"}]}],"title":"Stable MR4.5 for 192 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.7","upperLimit":"60.0","value":"48.8"}]}],"title":"Stable MR4.5 for 240 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32.1","upperLimit":"54.1","value":"42.9"}]}],"title":"Stable MR4.5 for 288 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.8","upperLimit":"50.5","value":"39.3"}]}],"title":"Stable MR4.5 for 336 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.6","upperLimit":"46.9","value":"35.7"}]}],"title":"Stable MR4.5 for 384 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.3","upperLimit":"42.0","value":"31.0"}]}],"title":"Stable MR4.5 for 432 weeks"}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"}],"units":"Participants"}],"description":"The proportion of patients who were in stable MR4.5 after achieving a response in the NTRI phase at multiple timepoints was calculated by dividing the number of participants achieving MR4.5 any time during the NTRI phase and having the same response at those timepoints after the first achievement of MR4.5, irrespective of whether there was loss of MR4.5 in between, by the number of patients who achieved MR4.5 at any time during the NTRI phase.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who experienced loss of major molecular response during the treatment-free remission (TFR) phase entered the nilotinib treatment re-initiation (NTRI) phase. During this phase, nilotinib treatment was re-initiated at a dose of 300 mg twice daily.","id":"OG000","title":"NTRI Phase"}],"paramType":"NUMBER","populationDescription":"The nilotinib treatment re-initiation (NTRI) safety set included all participants who achieved who achieved MR4.5 at least once in nilotinib re-initiation phase","reportingStatus":"POSTED","timeFrame":"Weeks 48, 96, 144, 192, 240, 288, 336, 384, and 432 after first achievement of MR4.5 during the nilotinib re-initiation phase","title":"Percentage of Participants With Stable Molecular Response 4.5 (MR4.5) at Multiple Time Points After First Achievement During Nilotinib Re-Initiation","type":"SECONDARY","unitOfMeasure":"percentage of participants"}